Kite Pharma, Inc. 4
4 · Kite Pharma, Inc. · Filed Jun 22, 2017
Insider Transaction Report
Form 4
BONDERMAN DAVID
Director
Transactions
- Award
Common Stock
2017-06-20+2,410→ 4,360 total - Award
Director Stock Option (Right to Buy)
2017-06-20+8,810→ 8,810 totalExercise: $91.21Exp: 2027-06-19→ Common Stock (8,810 underlying)
Holdings
- 2,408,084(indirect: See footnote)
Common Stock
Footnotes (2)
- [F1]The securities are held in the name of the Bonderman Family Limited Partnership ("BFLP") of which Mr. Bonderman is a limited partner. Wildcat Capital Management, LLC ("Wildcat") has dispositive and voting power over the shares held by BFLP pursuant to the terms of an investment management agreement to which Wildcat, Mr. Bonderman and BFLP are parties. Mr. Bonderman disclaims beneficial ownership of such shares held by BFLP except to the extent of his pecuniary interest therein.
- [F2]The stock option shall vest in 12 successive equal monthly installments following the date of grant.